 Pfizer Inc. PFE, 0.58 and German partner BioNTech SE BNTX, 0.82 said Friday a new analysis of data reviewing the immune response created by the omicron BA.4BA.5 adapted bivalent COVID vaccine showed strong results against newer omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1. The data, which has been posted on the preprint server bioRxiv, show that the booster induces a greater increase in neutralizing antibody titers than the companies original COVID-19 vaccine against these emerging omicron sublineages. 